Abstract
We report here the management of skin toxicity induced by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (MAbs) administration in our institute. Thirty patients treated advanced colorectal cancer with EGFR-targeted MAbs were retrospectively analyzed for antitumor effect, time to treatment failure (TTF), and skin-related toxicity. Cmab was administrated to 27 patients, and Pmab was administrated to 6 patients. Overall response rate was 24.2% (8 PR; 4 SD; 19 PD; NE 2), and disease control rate was 36.4%. Skin toxicity of all grades was observed in 23 cases with Cetuximab and in 5 cases with Panitumumab, respectively. Grade 3 toxicity of skin reaction was observed in 3 cases. No patient was interrupted their treatment with EGFR-targeted MAbs by skin toxicity. TTF was 4.7 months in all case. Treatment for advanced colorectal cancer with EGFR-targeted MAb was tolerated with acceptable efficacy under interdisciplinary team approach with trained pharmacists and nurses in our institute.
